Literature DB >> 26482389

Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma.

Xiao-Xin Wu1, Hai-Nv Gao1, Hai-Bo Wu1, Xiu-Ming Peng1, Hui-Lin Ou1, Lan-Juan Li2.   

Abstract

In January 2015, there was an outbreak of avian-origin influenza A (H7N9) virus in Zhejiang Province, China. A 45-year-old man was admitted to the First Affiliated Hospital of Zhejiang University with a high fever that had lasted 7 days, chills, and a cough with yellow sputum. Laboratory testing confirmed infection with the H7N9 virus, likely obtained from contact with poultry at a local live poultry market. A large dense shadow was apparent in the patient's left lung at the time of admission. Treatment with oseltamivir (75mg twice daily) did not improve the patient's condition. The decision was made to try using convalescent plasma to treat the infection. Convalescent plasma was administered 3 days after the patient was admitted to the hospital and led to a marked improvement. To our knowledge, this is the first report of the successful use of convalescent plasma to treat a case of H7N9 infection in China. These results suggest that the combination of convalescent plasma and antiviral drugs may be effective for the treatment of avian-origin H7N9 infection.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Convalescent plasma; H7N9; Oseltamivir

Mesh:

Substances:

Year:  2015        PMID: 26482389     DOI: 10.1016/j.ijid.2015.10.009

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  26 in total

1.  The convalescent sera option for containing COVID-19.

Authors:  Arturo Casadevall; Liise-Anne Pirofski
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

2.  H7N9 avian influenza A virus in China: a short report on its circulation, drug resistant mutants and novel antiviral drugs.

Authors:  Bao Danqi; Zejun Li; Qinfang Liu; Juergen A Richt
Journal:  Expert Rev Anti Infect Ther       Date:  2017-07-17       Impact factor: 5.091

Review 3.  Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines.

Authors:  Yinan Xiao; Hanyue Xu; Wen Guo; Yunuo Zhao; Yuling Luo; Ming Wang; Zhiyao He; Zhenyu Ding; Jiyan Liu; Lei Deng; Fushen Sha; Xuelei Ma
Journal:  Mol Biomed       Date:  2020-12-03

4.  Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial.

Authors:  John H Beigel; Evgenia Aga; Marie-Carmelle Elie-Turenne; Josalyn Cho; Pablo Tebas; Carol L Clark; Jordan P Metcalf; Caroline Ozment; Kanakatte Raviprakash; Joy Beeler; H Preston Holley; Stephanie Warner; Carla Chorley; H Clifford Lane; Michael D Hughes; Richard T Davey
Journal:  Lancet Respir Med       Date:  2019-09-30       Impact factor: 30.700

Review 5.  The role of adjuvant immunomodulatory agents for treatment of severe influenza.

Authors:  David S Hui; Nelson Lee; Paul K Chan; John H Beigel
Journal:  Antiviral Res       Date:  2018-01-08       Impact factor: 5.970

6.  Influenza A(H7N9) Virus Antibody Responses in Survivors 1 Year after Infection, China, 2017.

Authors:  Mai-Juan Ma; Cheng Liu; Meng-Na Wu; Teng Zhao; Guo-Lin Wang; Yang Yang; Hong-Jing Gu; Peng-Wei Cui; Yuan-Yuan Pang; Ya-Yun Tan; Hui Hang; Bao Lin; Jiang-Chun Qin; Li-Qun Fang; Wu-Chun Cao; Li-Ling Cheng
Journal:  Emerg Infect Dis       Date:  2018-04-17       Impact factor: 6.883

7.  A potentially effective treatment for COVID-19: A systematic review and meta-analysis of convalescent plasma therapy in treating severe infectious disease.

Authors:  Mengyao Sun; Yinghui Xu; Hua He; Li Zhang; Xu Wang; Qing Qiu; Chao Sun; Ye Guo; Shi Qiu; Kewei Ma
Journal:  Int J Infect Dis       Date:  2020-07-04       Impact factor: 3.623

Review 8.  Convalescent plasma: possible therapy for novel coronavirus disease 2019.

Authors:  Huiling Cao; Yuan Shi
Journal:  Transfusion       Date:  2020-05-02       Impact factor: 3.157

9.  Pandemic COVID-19: Current status and challenges of antiviral therapies.

Authors:  Winglam Chan; Betsy He; Xiong Wang; Ming-Liang He
Journal:  Genes Dis       Date:  2020-07-07

Review 10.  Novel therapeutic approaches for treatment of COVID-19.

Authors:  Nikoo Hossein-Khannazer; Bahare Shokoohian; Anastasia Shpichka; Hamid Asadzadeh Aghdaei; Peter Timashev; Massoud Vosough
Journal:  J Mol Med (Berl)       Date:  2020-06-03       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.